Changes to certain s100 programs

Page last updated: 1 February 2019

From 1 February 2019, changes to the Pharmaceutical Benefits Scheme (PBS) restrictions for growth hormone (GH) treatment (paediatric use), which set out the eligibility requirements for PBS subsidy, are being introduced.  The following document provides information specific to these changes:

From 1 December 2018, there will be an amendment to the current listing of growth hormone (somatropin) on the Pharmaceutical Benefits Schedule (PBS) and additional access to growth hormone will be available to adults with severe growth hormone deficiencies and substantially impaired quality of life. The following Frequently Asked Questions document provides information specifically related to this amendment:

In 2015, changes were made to certain Section 100 (s100) programs under the PBS.  These changes, which included the introduction of community access arrangements for a number of medicines available under the Highly Specialised Drugs Program, were recommended by the Pharmaceutical Benefits Advisory Committee. Frequently Asked Questions that outline the changes have been developed to assist prescribers, suppliers and patients.